What are the indications and recommended dosing for promethazine (Phenergan) in adults and children?

Promethazine (Phenergan) Indications and Dosing

Promethazine is indicated for allergic conditions, nausea/vomiting, sedation, and as an adjunct to anesthesia, with FDA-approved dosing of 12.5-25 mg IV (diluted, infused slowly) or 25-50 mg IM for adults, and is contraindicated in children under 2 years of age. 1

Primary Indications

Allergic Conditions

• Adult dose: 25 mg IV/IM 1
• May repeat within 2 hours if necessary
• Transition to oral route as soon as circumstances permit
• For allergic reactions to blood/plasma: 25 mg 1

Nausea and Vomiting

• Adult dose: 12.5-25 mg IV/IM 1
• Do not repeat more frequently than every 4 hours
• Important caveat: Antiemetics should not be used for vomiting of unknown etiology in children and adolescents 1
• When used for postoperative nausea/vomiting, reduce concomitant analgesic and barbiturate doses accordingly 1

Sedation

• Adult dose (hospitalized patients): 25-50 mg for nighttime sedation 1

Preoperative/Postoperative Adjunct

• Adult dose: 25-50 mg combined with appropriately reduced doses of analgesics and atropine-like drugs 1
• Reduce concomitant analgesic or hypnotic medication doses 1

Obstetrics

• Early labor: 50 mg for sedation and relief of apprehension 1
• Established labor: 25-75 mg (average 50 mg) with reduced narcotic dose 1
• May repeat once or twice at 4-hour intervals
• Maximum: 100 mg total in 24 hours during labor 1

Pediatric Dosing (≥2 Years Old)

Critical restriction: Promethazine is contraindicated in children under 2 years of age due to respiratory depression risk 1

For children ≥2 years:

• Dose should not exceed half the adult dose 1
• Use lowest effective dose 1
• Avoid concomitant respiratory depressants 1
• Premedication adjunct: 1.1 mg/kg with reduced narcotic/barbiturate doses 1

Administration Guidelines

Intramuscular (Preferred Route)

• Deep IM injection is the preferred route due to severe tissue injury risks with IV administration 1, 2

Intravenous (Use with Extreme Caution)

Adults:

• Must dilute before administration 1
• Infuse slowly: 25 mg/min to minimize hypotension 3
• Use large vein, preferably central venous catheter 1
• Do NOT use hand or wrist veins 1
• Infusion time: 20-40 minutes 1
• Maximum concentration after dilution: 1 mg/mL 1

Dilution protocol:

• 12.5-50 mg: dilute in 50 mL 0.9% sodium chloride 1
• 75 mg: dilute in 100 mL 0.9% sodium chloride 1
• Maximum infusion rate: 2.5-5 mL/minute depending on dose 1

Pediatric IV (≥2 years):

• Maximum concentration: 1 mg/mL 1
• Maximum infusion rate: 1.25 mL/minute 1
• Use central venous access when possible 1

Critical safety measure: If pain occurs during IV infusion, immediately discontinue and evaluate for arterial injection or extravasation 1

Mechanism and Pharmacokinetics

Promethazine is a phenothiazine with:

• Antihistamine (H1 receptor antagonist) effects 3
• Sedative properties 3
• Antiemetic action (blocks dopaminergic receptors) 4
• Anticholinergic effects 3

Onset: Within 5 minutes IV 4, 3
Duration: 4-6 hours 4, 3
Half-life: 9-16 hours 4, 3

Adjunctive Use in Procedures

Promethazine has been used as adjunct sedation for endoscopic procedures 4:

• Dose: 12.5-25 mg IV (infused slowly) 4
• Total dose range: 25-100 mg when combined with narcotics/benzodiazepines 4
• Requires reduction in standard sedation agent doses 4

Breakthrough Antiemetic Therapy

For chemotherapy-induced nausea/vomiting when first-line agents fail 5:

• Promethazine dose: 12.5-25 mg PO/IV (central line only) every 4-6 hours 5
• Alternative: 25 mg suppository PR every 6 hours 5
• Add as agent from different drug class to current regimen 5

Adverse Effects

Common:

• Hypotension (especially with rapid IV infusion) 4, 3
• Sedation 4
• Respiratory depression 4, 3

Serious:

• Severe tissue injury: burning, pain, thrombophlebitis, tissue necrosis, gangrene with extravasation or intra-arterial injection 3, 2
• Neuroleptic malignant syndrome 4, 3
• Extrapyramidal effects (restlessness to oculogyric crises) 4, 3

Critical Safety Considerations

The FDA updated labeling in December 2023 emphasizing:

1. IM administration is preferred over IV 1, 2
2. Mandatory dilution and slow infusion for IV use 1
3. Use of large veins, preferably central access 1
4. Immediate discontinuation if injection site pain occurs 1

Many institutions have removed injectable promethazine from formularies due to limb-threatening complications from extravasation 2, 6. When used, institutional policies should mandate proper dilution, administration technique, and monitoring 2, 6.

Dose Reduction Requirements

When promethazine is used with other CNS depressants:

• Reduce narcotic doses 1
• Reduce barbiturate doses 1
• Reduce other sedative doses 4

Lower doses (6.25 mg IV) provide comparable antiemetic efficacy to standard doses (12.5 mg) with less sedation 7, 8, though these lower doses are not FDA-approved.